WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Bayer Starts Phase III Trial with Florbetaben 01 December 2009
Bayer starts pivotal Phase III trial with Florbetaben 01 December 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer 23 October 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer 23 October 2009
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival 24 September 2009
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 21 September 2009
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 21 September 2009
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S. 03 September 2009
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF) 31 August 2009
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban 31 August 2009
Bayer acquires exclusive rights to Bioton's insulin SciLin® 10 July 2009
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US 09 July 2009
Bayer files patent infringement lawsuit against Teva 02 July 2009
Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets 30 June 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer 02 June 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer 02 June 2009
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® 29 May 2009
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer 21 May 2009
Qlaira® - innovative estradiol-based oral contraceptive available in Europe 15 May 2009
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch 07 May 2009
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer raises its brand profile

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.